Last reviewed · How we verify
Sildenafil 20 MG
At a glance
| Generic name | Sildenafil 20 MG |
|---|---|
| Also known as | Sildenafil Citrate 20 mg ( Respatio® 20 mg), Experimental: Smoking Cessation Group 1, Experimental: Non-Smokers Group 1, sildenafil |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Asciminib With or Without Sildenafil for Brain Tumors (EARLY_PHASE1)
- Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (PHASE2)
- IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (PHASE1)
- Sildenafil for Microvasculopathy in Chronic TBI (PHASE2)
- Sildenafil for Early Pulmonary Vascular Disease in Scleroderma (PHASE2)
- The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients (NA)
- Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy (NA)
- Sildenafil for Treatment of Choroidal Ischemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sildenafil 20 MG CI brief — competitive landscape report
- Sildenafil 20 MG updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI